Austin John provides a guide to obtaining the Fierce Deity armor and sword without the use of Amiibo. 'National emergency': After assassination attempt, White House urges Congress to fund DHS Capital ...

A Canadian who has worked in the gaming industry for over two decades, Beck grew up on games such as Final Fantasy and Super Mario Bros. He specalizes in roleplaying games, but covers titles in almost ...

Retinal diseases are among the fastest growing causes of blindness, having a profound impact on patients’ independence and quality of life. As the global ophthalmology community gathers at the ...

Add Yahoo as a preferred source to see more of our stories on Google. Maryland Gov. Wes Moore says he would support his son's gender transition as a minor on the "PBD Podcast," sparking fierce ...

Condoms can be purchased almost anywhere, from big retailers to small convenience stores. The same can’t be said for female birth control. One company is trying to change that. Cadence OTC sells the ...

The Netherlands is gearing up for a new tax on paper profits, sparking public and political opposition and opening another front in the international push to target the wealthy. From 2028, individual ...

WSJ’s Konrad Putzier explains the factors that led inflation to surge in March and discusses the implications for the U.S. economy and the Fed. Photo: Nam Y. Huh/Associated Press When Shannon ...

In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German company BioNTech is slashing a large chunk of its manufacturing footprint, ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict the asset could beat out AbbVie’s Skyrizi ...

Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the drugmaker to advance a Tourette syndrome candidate that is on the cusp of approval. The deal ...

The Trump administration is testing out a new 10-year program for value-based chronic condition management that leans heavily on technology and artificial intelligence to scale to large populations of ...